https://www.selleckchem.com/products/mitomycin-c.html These findings contradict previous reports of the antinociceptive properties of the P. nitida alkaloids and the traditional use of akuamma seeds as analgesics. Nevertheless, their opioid-preferring activity does suggest the akuamma alkaloids provide distinct scaffolds from which novel opioids with unique pharmacologic properties and therapeutic utility can be developed.Clearance of peripheral amyloid-β (Aβ) has been demonstrated to be promising for overcoming the blood-brain barrier (BBB) hurdle to eliminate brain-derived Aβ associated with Alzheimer's disease (AD). Even so, current developed therapeutic assays for clearance of peripheral Aβ are still facing challenges on how to avoid interference of certain biological molecules and prevent triggering the activation of immune responses and blood clotting. Here, a biomimetic nanozyme (Cu x O@EM-K) with augmented protein adsorption resistance, minimized immunogenicity, and enhanced biocompatibility is designed and synthesized. The Cu x O@EM-K is made of Cu x O nanozyme wrapped with modified 3xTg-AD mouse erythrocyte membrane with Aβ-targeting pentapeptide KLVFF. KLVFF serves as Aβ-specific ligand that works together with erythrocyte membrane to selectively capture Aβ in the blood. Meanwhile, the erythrocyte membrane coating prevents protein coronas formation and thus retains Aβ-targeting ability of Cu x O@EM-K in biological fluids. More importantly, the Cu x O core with multiple antioxidant enzyme-like activities stabilizes the outer erythrocyte membrane and simultaneously mitigates Aβ-induced membrane oxidative damage, which enables the extended systemic circulation indispensable for adsorbing Aβ. In vivo studies demonstrate that Cu x O@EM-K not only reduces Aβ burden in the blood and brain but also ameliorates memory deficits in the widely used 3xTg-AD mouse model. Moreover, Cu x O@EM-K shows no apparent toxicity in 3xTg-AD mice. Overall, this work provides an ex